CIK 0001386570 · Large accelerated filer
Niagen Bioscience, Inc.
Sign in to watch- Ticker
- NAGE
- Exchange
- Nasdaq
- Industry
- Medicinal Chemicals & Botanical Products
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 262940963
- Phone
- 310-388-6706
- Business address
- 10900 WILSHIRE BLVD, SUITE 600, LOS ANGELES, CA, 90024
- Former names
- ChromaDex Corp., CODY RESOURCES, INC.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-06-24 | Rubin Steven D Director | Grant or award · Stock Option (right to buy) | +20,000 | 20,000 | ||
| 2025-06-24 | Ng Wang Yu Gary Director | Grant or award · Stock Option (right to buy) | +20,000 | 20,000 | ||
| 2025-06-24 | Cohen Ann Director | Grant or award · Stock Option (right to buy) | +20,000 | 20,000 | ||
| 2025-06-24 | Jaksch Frank L Jr Director | Grant or award · Stock Option (right to buy) | +20,000 | 20,000 | ||
| 2025-04-09 | Fried Robert N Chief Executive Officer | Option exercise | +66,667 | $3.30 | $220K | 1,038,981 |
| 2025-04-09 | Fried Robert N Chief Executive Officer | Option exercise · Stock Options (right to buy) | −66,667 | 0 | ||
| 2025-03-07 | Lopez Carlos Luis SVP, General Counsel | Purchase | +273 | $7.86 | $2K | 2,251 |
| 2025-02-25 | Fried Robert N Chief Executive Officer | Grant or award · Performance Stock Unit | +1,518,600 | 1,518,600 | ||
| 2025-02-12 | Lopez Carlos Luis SVP, General Counsel | Grant or award · Employee Stock Options (right to buy) | +19,691 | 19,691 | ||
| 2025-02-12 | Pamir Ozan Chief Financial Officer | Grant or award · Employee Stock Options (right to buy) | +17,230 | 17,230 | ||
| 2025-02-12 | Fried Robert N Chief Executive Officer | Grant or award · Employee Stock Options (right to buy) | +492,278 | 492,278 | ||
| 2024-12-13 | Jaksch Frank L Jr Director | Option exercise | +50,001 | $3.66 | $183K | 281,340 |
| 2024-12-13 | Jaksch Frank L Jr Director | Sale | −37,161 | $6.19 | $230K | 244,179 |
| 2024-12-13 | Jaksch Frank L Jr Director | Option exercise · Employee Stock Options (right to buy) | −50,001 | 0 | ||
| 2024-11-22 | Pamir Ozan Chief Financial Officer | Purchase | +2,907.2 | $7.36 | $21K | 2,907.2 |
| 2024-10-21 | Pamir Ozan Chief Financial Officer | Grant or award · Employee Stock Options (right to buy) | +146,544 | 146,544 | ||
| 2024-08-23 | Patrick Kristin Director | Option exercise | +3,000 | $1.64 | $5K | 3,000 |
| 2024-08-23 | Patrick Kristin Director | Option exercise | +20,000 | $1.67 | $33K | 23,000 |
| 2024-08-23 | Patrick Kristin Director | Sale | −23,000 | $3.57 | $82K | 0 |
| 2024-08-23 | Patrick Kristin Director | Option exercise · Stock Option (right to buy) | −3,000 | 17,000 |
Page 2 of 6 · 118 trades